Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2008

01-03-2008 | Original Paper

Epigallocatechin-3-gallate induces apoptosis and cell cycle arrest in HTLV-1-positive and -negative leukemia cells

Authors: S. Harakeh, K. Abu-El-Ardat, M. Diab-Assaf, A. Niedzwiecki, M. El-Sabban, M. Rath

Published in: Medical Oncology | Issue 1/2008

Login to get access

Abstract

The objective of this study is to evaluate the efficacy of epigallocatechin gallate against ATL cells. The anti-proliferative and pro-apoptotic effects of EGCG were evaluated in HTLV-1-positive and -negative cells. EGCG exhibited a marked decrease in proliferation of ATL cells at 96 h of treatment. The results indicated that TGF-α was down-regulated whereas levels of TGF-β2 increased. Cell cycle distribution analysis revealed an increase in cells in the pre-G1 phase which was confirmed by ELISA. The results on proteins showed an up-regulation of p53, Bax and p21 protein levels while the levels of Bcl-2α were down-regulated.
Literature
1.
Hare Y. Green tea: health benefits and applications. New York: Marcel Dekker, Basel; 2001.
2.
Erba D, Riso P, Colombo A, Testolin G. Supplementation of Jurkat T cells with green tea extract decreases oxidative damage due to iron treatment. J Nutr 1999;129:2130–4.PubMed
3.
Kawai K, et al. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp 120 binding. J Allergy Clin Immunol 2003;112:951–7.PubMedCrossRef
4.
Hayakawa S, et al. Apoptosis induction by epigallocatechin gallate involves its binding to Fas. Biochem Biophys Res Commun 2001;285:1102–6.PubMedCrossRef
5.
Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells. Arch Biochem Biophys 2000;376:338–46.PubMedCrossRef
6.
Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000;164:82–90.PubMedCrossRef
7.
Fujiki HJ, et al. Cancer inhibition by green tea. Mutation Res 1998;402:307–10.PubMed
8.
Wang YC, Bachrach U. The specific anti-cancer activity of green tea (-)-epigallocatechin-3-gallate (EGCG). Amino Acids 2002;22:131–43.PubMedCrossRef
9.
Li H, et al. Green tea polyphenols induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn J Cancer Res 2000;91:34–40.PubMed
10.
Roy M, Chakrabarty S, Sinha D, Bhattacharya R, Siddiqi M. Anticlastogenic, antigenotoxic and apoptotic activity of epigallocatechin gallate: a green tea polyphenol. Mutation Res 2003;523–524:33–41.PubMed
11.
Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing’s Sarcoma SK-ES.1. Oncol Rep 2005;13:253–7.PubMed
12.
Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. In vivo antitumor effect of ascorbic acid, lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: evaluation of tumor growth and immunohistochemistry. In Vivo 2005;19:179–83.PubMed
13.
Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. In vitro and in vivo antitumorigenic activity of a mixture of lysine, proline, acorbic acid, and green tea extract on human breast cancer lines MDA-MB-231 and MCF-7. Med Oncol 2005;22:129–38.PubMedCrossRef
14.
Hinuma Y, et al. Transforming genes in human leukemia cells. PNAS 1985;66:1371–8.
15.
Kaplan J, Khabbaz R. The epidemiology of human T-lymphotropic virus type I and II. Med Virol 1993;3:137–48.CrossRef
16.
Gessain A. Epidemiology of HTLV-1 and associated diseases. In: Höllsberg P, Hafler DA, editors. Human T-cell lymphotropic virus type 1. John Willey & Sons Ltd.; 1996. p. 33–64.
17.
Hermine O, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alpha. N Engl J Med 1995;332:1749–51.PubMedCrossRef
18.
Macchi B, Faraoni I, Zhang J, Grelli S, Favalli C, Mastino A, et al. AZT inhibits the transmission of human T cell leukemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J Gen Virol 1997;78:1007–16.PubMed
19.
Zhang J, Balestrieri E, Grelli S, Matteucci C, Pagnini V, D’Agostini C, et al. Efficacy of 3′-azido 3′deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells. Virus Res 2001;78:67–78.PubMedCrossRef
20.
Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naïve and pretreated adult T-cell leukemia/lymphoma patients. J Acq Immun Defic Synd Hum 1996;R13(Suppl. 1):5186–90.
21.
Hsu TC, et al. Comparative efficacy as antioxidants between ascorbic acid and epigallocatechin gallate on cells of two human lymphoblastoid lines. Cancer Genet Cytogenet 2001;124:169–71.PubMedCrossRef
22.
Mitscher LA, et al. Chemoprotection: a review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents. Med Res Rev 1997;17:327–65.PubMedCrossRef
23.
Yang CS, Yang GY, Landau JM, Kim S, Liao J. Exp Lung Res 1998;24:629.
24.
Otsuka T, et al. Growth inhibition of leukemic cells by (-)-epigallocatechin gallate: the main constituent of green tea. Life Sci 1998;63:1397–403.PubMedCrossRef
25.
Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)-epigallocatechin-3-gallate induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003;410:177–85.PubMedCrossRef
26.
Kanai M, et al. TGF-α inhibits apoptosis of murine gastric pit cells through an NF-κB-dependent pathway. Gastroenterology 2001;121:56–67.PubMedCrossRef
27.
Javelaud D, Mauviel A. Mammalian transforming growth factors-βs: Smad signaling and physio-pathalogical roles. Int J Biochem Cell Biol 2004;36:1161–5.PubMedCrossRef
28.
Lee DK, et al. The human papilloma virus E7 oncoprotein inhibits transforming growth factor-β signaling by blocking binding of the Smad complex to its target sequence. J Biol Chem 2002;277:38557–64.PubMedCrossRef
29.
Saeki K, et al. Cell density-dependent apoptosis in HL-60 cells, which is mediated by an unknown soluble factor, is inhibited by transforming growth factor beta 1 and overexpression of Bcl-2. J Biol Chem 2000;272:3–10.
30.
Cerwenka A, Kovar H, Majdic O, Holter W. Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-beta 1. J Immunol 1996;156:459–64.PubMed
31.
Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor β (TGF-β) production by murine CD4+ T cells. J Exp Med 1998;188:1849–57.PubMedCrossRef
32.
Patil S, et al. Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-β-induced growth inhibition and apoptosis. J Biol Chem 2000;275:38363–70.PubMedCrossRef
33.
Inmann GJ, Allday MJ. Apoptosis induced by TGF-β1 in Burkitt’s Lymphoma cells is caspase 8 dependent but is death receptor independent. J Immunol 2000;165:2500–10.
34.
Wolfraim LA, Walz TM, James Z, Fernandez T, Letterio JJ. p21Cip1 and p27Kip1 act in synergy of naïve T cells to TGF-beta-mediated G1 arrest through modulation of IL-2 responsiveness. J Immunol 2004;173:3093–102.PubMed
35.
36.
Arnulf B, et al. Human T-cell lymphotropic virus oncoprotein tax represses TGF-β1 signaling in human T cells Via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood 2002;100:4129–37.PubMedCrossRef
37.
Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137–61.PubMedCrossRef
38.
Dotto GP. p21WAF1/Cip1: more than a break to the cell cycle? Biochem Biophys Acta 2000;1471:M43–56.PubMed
39.
Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 1999;287:821–8.PubMedCrossRef
40.
41.
42.
Dupont S, et al. Convergence of p53 and TGF-beta signaling networks. Cancer Lett 2004;213:129–38.PubMedCrossRef
43.
Haupt S, Haupt Y. Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin Cancer Biol 2004;14:244–52.PubMedCrossRef
44.
May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999;18:7621–36.PubMedCrossRef
45.
Heiser D, Labi V, Erlacher M, Villunger A. The Bcl-2 protein family and its role in the development of neoplastic disease. Exp Gerontol 2004;39:1125–35.PubMedCrossRef
46.
Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? J Pathol 2005;205:206–20.PubMedCrossRef
47.
Kuo P, Lin CC. Green tea constituent (-)-epigallocatechin-3-gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. J Biomed Sci 2003;10:219–27.PubMed
48.
Nihal M, Ahmad N, Mukhtar H, Wood GS. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 2005;114:513–21.PubMedCrossRef
49.
Yang CS, Hong J, Hou Z, Sang S. Green tea polyphenols: antioxidative and prooxidative effects. J Nutr 2004;134:3181S.PubMed
50.
Szeto YT, Benzie IFF. Effects of dietary antioxidants on human DNA ex vivo. Free Radic Res 2002;36:113–8.PubMedCrossRef
Metadata
Title
Epigallocatechin-3-gallate induces apoptosis and cell cycle arrest in HTLV-1-positive and -negative leukemia cells
Authors
S. Harakeh
K. Abu-El-Ardat
M. Diab-Assaf
A. Niedzwiecki
M. El-Sabban
M. Rath
Publication date
01-03-2008
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 1/2008
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-007-0036-6

Other articles of this Issue 1/2008

Medical Oncology 1/2008 Go to the issue

Original Paper

Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey

Original Paper

Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors

Original Paper

Anaemia of cancer: an overview of mechanisms involved in its pathogenesis

Original Paper

Mature results of neoadjuvant chemotherapy followed by radiotherapy in nasopharyngeal cancer: is it really old fashioned?

Original Paper

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care

CASE

Breast cancer with an unusual leukemia-like presentation: case report and literature review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits